DOC
2,5-dimethoxy-4-chloroamphetamine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
DOC (2,5-dimethoxy-4-chloroamphetamine) is a synthetic psychedelic of the phenethylamine class. It belongs to the DOx series — a family of halogenated compounds closely related to DOM, active at sub-milligram doses. It activates serotonin receptors in the brain, disrupting normal sensory filtering and producing its characteristic psychedelic effects.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DOM, DOI, DOB show less
First synthesized in 1973 to study how halogen substitutions affect psychedelic potency,[3] DOC was later characterized by Alexander Shulgin in PiHKAL (1991).[4] Starting in 2004, it appeared in drug markets on blotter paper, frequently sold as LSD, leaving buyers unprepared for its far greater potency and longer duration.[5] The WHO recommended international scheduling in 2019, citing public health risk and no recognized therapeutic use.[5]
Subjective effects include geometric visual patterns, brightened colors, time alteration, accelerated thinking, and strong physical stimulation. The experience is electrically charged and bodily present — more stimulating than LSD, with a peak that plateaus for hours rather than tapering smoothly. Pronounced body load, vasoconstriction, and inability to sleep through the prolonged tail are characteristic unsought effects.
DOC produces no physical dependence, and the lethal dose in humans is unknown — two deaths appear in published case reports.[6][7] The main acute danger is a sympathomimetic crisis — seizures, dangerous overheating, and muscle breakdown — worsened by frequent misrepresentation as LSD.[5] No controlled human studies exist; current understanding comes from case reports, animal data, and analogy to related compounds.[5]
History[edit]
Discovery
DOC was first synthesized in 1973 to study how halogen substitutions at the 4-position of the ring affect psychedelic potency relative to DOM.[3] Alexander Shulgin self-tested it and documented it as entry #64 in PiHKAL (1991), establishing the active dose range and describing an archetypical psychedelic experience lasting 12–24 hours.[4]
Forensic Emergence
DOC appeared in European forensic notifications in 2004 and US seizures by 2006–2009, mostly as blotter paper sold as LSD.[5] Because DOC is far longer-lasting and more potent by weight, buyers using LSD doses were caught off guard.[8] The first death attributed solely to DOC was reported in 2014.[6]
Scheduling and Modern Status
The WHO recommended DOC be placed in Schedule I of the 1971 Convention on Psychotropic Substances in 2019, citing public health risk and no therapeutic value.[5] No clinical research has investigated DOC for any therapeutic purpose. It remains primarily a forensic concern and a pharmacological reference compound within the DOx series.[9]
The name DOC follows DOx series convention: DO for 2,5-dimethoxy, C for the 4-chloro substituent — parallel to DOM (methyl), DOI (iodo), and DOB (bromo). The compound has no widely recognized street names.
Chemistry[edit]
Structural Class
DOC belongs to the DOx series — a family of 2,5-dimethoxy-4-substituted phenylisopropylamine psychedelics that includes DOM, DOI, and DOB.[9] The distinguishing feature of DOC is a chlorine atom at the 4-position of the ring. The amphetamine backbone gives the DOx series greater metabolic stability and longer duration than the related 2C-x phenethylamines.
Molecular Properties
DOC's molecular formula is C₁₁H₁₆ClNO₂ (molecular weight 229.70 g/mol as free base; 266.17 g/mol as HCl salt).[1] The 2,5-dimethoxy pattern on the phenyl ring is shared across all DOx compounds and is essential for strong serotonin receptor binding.[5]
Pharmacology[edit]
Mechanism of Action
DOC is a partial agonist at serotonin receptors — primarily the 5-HT₂A type. Activating these receptors triggers a signaling cascade that raises cortical excitability and disrupts the brain's normal filtering of sensory information.[2] This is what drives the visual distortions and loosened thinking that define the DOC experience.
Despite sharing an amphetamine-like chemical backbone with conventional stimulants, DOC does not release dopamine, serotonin, or norepinephrine.[10] Its effects are entirely receptor-driven — confirmed in animal studies showing DOC behaves like serotonergic psychedelics, not stimulants.[5][11]
Pharmacokinetics
No controlled human pharmacokinetic studies exist for DOC — onset timing, half-life, and bioavailability are all unknown. The liver enzyme CYP2D6 handles most of DOC's breakdown, removing chemical groups to produce its main metabolites.[12] DOC weakly inhibits CYP2D6 in return, though this effect is unlikely to cause significant interactions at typical doses.[12]
Neuroscience[edit]
Where It Acts
DOC targets serotonin receptors concentrated in the deep layers of the cerebral cortex. When these fire, they amplify excitatory brain signaling and disrupt the system that normally filters sensory information before it reaches conscious awareness.[13] This is the leading explanation for DOC's visual distortions, sensory flooding, and loosened thinking.
DOC's potency at this pathway is confirmed by rodent behavioral studies[11] and its exceptionally strong receptor binding.[1] Whether DOC produces the same patterns of altered network activity seen with LSD and psilocybin has not been studied.
Theoretical Frameworks
Two ideas from psychedelic research offer context. The REBUS model proposes that serotonin receptor activation loosens the brain's predictive expectations, giving raw sensory experience more influence over conscious perception. The entropic brain hypothesis suggests psychedelics expand accessible brain states by increasing the randomness of spontaneous cortical activity. Neither has been directly tested in DOC studies.
Does DOC's amphetamine-based structure produce a different neural signature than tryptamine psychedelics like psilocybin, or lysergamides like LSD? How does its activity at two serotonin receptor subtypes shape the balance between visual effects and anxiety?
Subjective Effects[edit]
DOC delivers a long, electrically charged psychedelic experience. Intense visual distortion and cognitive loosening are shot through with persistent physical energy — a stimulation that keeps the body alert even as the mind ranges far. This gives DOC a driven, sometimes pressured character distinct from most other psychedelics.
Compared to LSD, DOC is more physically stimulating with a heavier body load, and its peak plateaus rather than tapering smoothly. Relative to psilocybin, it is more visually sharp, more energizing, and far longer-lasting — without the earthy sedation that typically characterizes tryptamine psychedelics.
Effect Grid
At common doses (1.5–2.5 mg oral), the full psychedelic experience manifests: pronounced open- and closed-eye visuals with geometric patterning, color shifting, drifting and morphing of surfaces, and tracers. Time distortion becomes significant. Thought acceleration and conceptual thinking intensify, with experiences described as "archetypical" psychedelia comparable to LSD or psilocybin.
Physically, tachycardia, stimulation, jaw tension, temperature dysregulation, and appetite suppression are common. The experience spans 12–20 hours and demands a full-day commitment. Sleep is impossible for most of the duration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Brightness alteration · Symmetrical texture repetition · Environmental patterning · Visual breathing · Depth perception distortion · Perspective distortion · Tracers · After-images · Visual diffraction · Music enhancement · Auditory enhancement · Dreaming suppression · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual morphing · Touch enhancement · Auditory distortion · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual haze / noise · Visual melting · Visual processing acceleration · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual acuity enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Visual breathing · Depth perception distortion · Perspective distortion · Tracers · After-images · Visual diffraction · Music enhancement · Auditory enhancement · Dreaming suppression · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual morphing · Touch enhancement · Auditory distortion · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual haze / noise · Visual melting · Visual processing acceleration · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual acuity enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Wakefulness · Appetite suppression · Restlessness · Insomnia · Spontaneous body sensations · Excessive sweating · Muscle tension · Dehydration sensation · Dry mouth · Body high · Heart rate perception changes · Physical fatigue · Body schema distortion · Nausea · Bodily pressures · Laughter fits · Motor control impairment · Tactile euphoria · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Involuntary body movements · Diarrhea · Sexual arousal enhancement · Bodily lightness · Headache · Kundalini-like energy · Nasal congestion · Nystagmus (eye wobbles) · Increased urination · Salivation · Vomiting · Motor control enhancement · Abnormal heartbeat · Seizure threshold reduction · Tactile hallucination
Insomnia · Spontaneous body sensations · Excessive sweating · Muscle tension · Dehydration sensation · Dry mouth · Body high · Heart rate perception changes · Physical fatigue · Body schema distortion · Nausea · Bodily pressures · Laughter fits · Tactile euphoria · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Involuntary body movements · Diarrhea · Sexual arousal enhancement · Bodily lightness · Headache · Kundalini-like energy · Nasal congestion · Nystagmus (eye wobbles) · Increased urination · Salivation · Vomiting · Motor control enhancement · Abnormal heartbeat · Seizure threshold reduction · Tactile hallucination
Novelty enhancement · Immersion enhancement · Thought connectivity · Aesthetic enhancement · Openness enhancement · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Increased nature relatedness · Introspection enhancement · Multiple thought streams · Creativity enhancement · Cognitive impairment · Confusion · Thought disorganization · Analysis enhancement · Memory suppression · Focus suppression · Memory fragmentation · Thought loops · Humor enhancement · Information processing enhancement · Motivation enhancement · Cognitive dysphoria · Focus enhancement · Memory replays · Synchronicity · Language enhancement · Compulsive redosing urge · Amnesia · Delusions · Delirium
Aesthetic enhancement · Openness enhancement · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Increased nature relatedness · Introspection enhancement · Multiple thought streams · Creativity enhancement · Cognitive impairment · Confusion · Thought disorganization · Analysis enhancement · Memory suppression · Focus suppression · Memory fragmentation · Thought loops · Humor enhancement · Information processing enhancement · Motivation enhancement · Cognitive dysphoria · Focus enhancement · Memory replays · Synchronicity · Language enhancement · Amnesia · Delusions · Delirium
Simultaneous emotions · Anxiety · Empathy enhancement · Catharsis · Irritability · Dysphoria · Mania
Catharsis · Irritability · Dysphoria
Social connection · Depersonalization · Trust enhancement · Communication enhancement · Ego inflation · Flow state · Sociability enhancement · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Ego inflation · Flow state · Sociability enhancement · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Time cessation
Non-dual awareness · Death-rebirth sequence · Entity contact · Transpersonal memory access
Recursive awareness
Timeline
First alerts appear 1–3 hours after oral ingestion: subtle mood shift, mild perceptual brightening, and a growing sense that something is changing. The slow onset is characteristic of the DOx class and may tempt impatient users to redose — a significant overdose risk.
Intensity builds steadily over 1–2 hours as visual and cognitive effects become unmistakable. Color enhancement, emerging geometric patterning, and increasing thought connectivity signal the approach of peak effects. Mild nausea, body tension, and rising heart rate are common.
The peak plateau spans 4–7 hours — a sustained maximum-intensity period that is unusually long among psychedelics. Pronounced visual distortions, profound time dilation, intense emotional amplification, and altered conceptual processing dominate. Physical stimulation and tachycardia persist throughout.
Effects remain clearly present but gradually diminish in intensity over 3–5 hours. Visual effects soften, cognitive alterations become more manageable, and a sense of returning normalcy alternates with residual waves of psychedelic perception. Physical stimulation persists.
A slow descent toward baseline over 2–4 hours. Residual visual and cognitive effects fade gradually. Fatigue from the extended experience becomes prominent.
A prolonged afterglow lasting 6–24 hours features residual mood changes, mild perceptual sensitivity, cognitive reflectiveness, and physical fatigue. Some users report difficulty sleeping even after subjective effects have resolved.
⚠ Do not drive or operate machinery until after a full night of restorative sleep following the experience, as residual impairment may persist well beyond perceived baseline return.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for DOC in humans, and the toxic dose is unknown.[5] Two deaths appear in published case reports — one in a 37-year-old male with no other substances besides caffeine,[6] and one in a young woman who experienced vomiting, seizures, and cardiac arrest.[7]
Acute Toxicity
Severe DOC poisoning presents as a sympathomimetic crisis: rapid heart rate, blood vessel constriction, seizures, dangerously elevated body temperature, and muscle breakdown. Symptoms can persist 24–33 hours.[5]
Heart and Circulation
DOC likely binds strongly to a serotonin receptor subtype linked to heart valve damage — the same mechanism implicated in damage seen with drugs like fenfluramine and MDMA.[14][15][16] No valve damage from DOC has been reported, but repeated heavy use carries a theoretical long-term cardiac risk.
Psychological Risks
DOC's 12–24-hour duration carries elevated risk of acute panic, anxiety spirals, and prolonged distress — especially in people who didn't know they were taking it.[8] Agitation and aggressive behavior have been documented in clinical cases.[17][5]
As a potent serotonin receptor activator, DOC carries the class-level risk of triggering latent psychotic disorders in predisposed individuals.inferred No data on persistent visual disturbances (HPPD) following DOC use have been published.
Tolerance and Dependence
Tolerance builds rapidly after a single dose, driven by downregulation.[2] Cross-tolerance with LSD, psilocybin, mescaline, and other DOx compounds is expected. Recovery timelines — approximately 3 days for tolerance to halve, 7 days for full reset — are inferred from class-level data, not DOC-specific studies.inferred
No dependence potential has been demonstrated in humans or animals.[5] Rapid tolerance functionally prevents compulsive redosing.
Drug Interactions
Tramadol: Classified as dangerous. Tramadol raises serotonin levels; combined with DOC's direct serotonin receptor activation, the two create additive risk of serotonin syndrome — dangerous overheating, agitation, and muscle rigidity.[18]
MAOIs: Monoamine oxidase inhibitors combined with serotonergic compounds risk serotonin syndrome. DOC acts through receptor binding rather than serotonin release, but the combination still introduces excess serotonergic stimulation.safety citation needed
SSRIs: Chronic SSRI use reduces the effects of serotonin-receptor psychedelics through receptor adaptation. A blunting of DOC's effects is expected by analogy with LSD.[19]
CYP2D6 substrates: DOC weakly inhibits the liver enzyme CYP2D6.[12] Interactions with medications processed by this enzyme are theoretically possible but unlikely at typical doses.
Contraindications
No DOC-specific contraindication data exist. The following are inferred from its pharmacological profile:
- Psychotic disorders or family history of psychosis: Serotonin receptor activation may trigger or worsen psychotic episodes inferred
- Bipolar disorder: Risk of triggering manic or mixed episodes inferred
- Heart conditions: Rapid heart rate and vasoconstriction documented in case reports[5]
- Seizure disorders: Seizures documented in severe intoxication; pre-existing epilepsy may lower the threshold[5]
- Pregnancy: No reproductive safety data exist safety citation needed
- Lithium: The combination with serotonergic psychedelics is associated with seizures and unpredictable intensification safety citation needed
Harm Reduction[edit]
Forms & Identification
DOC's most dangerous real-world characteristic is its frequent sale as LSD on blotter paper.[8][5] Ehrlich's reagent is the essential screening tool: it reacts with indole compounds like LSD but not with DOC. A negative result on a blotter sold as LSD is a strong indicator of substitution.
Any blotter-form psychedelic that has not been reagent-tested could be a DOx compound, an NBOMe, or another long-acting substitute with a fundamentally different risk profile.
Guidelines
- Test before use. Reagent test any blotter or powder. Ehrlich's reagent (negative = not an indole compound) is the minimum screen. A positive Marquis result is expected for DOC.
- Start low. DOC is active at sub-milligram doses. Use a precision milligram scale — volumetric dosing for solutions. Never eyeball powder.
- Wait before redosing. Onset may take 1–3 hours. Redosing before full onset is the most common path to overdose with long-acting psychedelics.
- Prepare the environment. Secure a comfortable, safe space for 18–24 hours. Stock water, light food, and comfort items. Remove access to vehicles.
- Arrange a sitter. Brief them on the expected duration and the possibility that reassurance may be needed well into the experience.
- Eat lightly beforehand. A small meal 2–3 hours before dosing reduces nausea without substantially delaying onset.
- Hydrate steadily. Sympathomimetic stimulation increases fluid needs over a very long experience.
Set & Setting
DOC's duration — potentially exceeding 20 hours — makes preparation more consequential than with most psychedelics. A full day and the following night should be kept clear of obligations. What feels manageable at hour 2 may become overwhelming by hour 12.
A trusted, sober sitter is strongly recommended, ideally one familiar with the compound's extended timeline. Mental state at dosing matters: DOC amplifies existing mood, and a 20-hour amplification of anxiety is qualitatively different from a 6-hour one.
Aftercare & integration. The extended duration means even a positive experience may leave significant physical and psychological residue. Sleep is often disrupted for 24–36 hours after dosing; planning for recovery sleep the following day is essential.
Physical aftercare should prioritize hydration, light nutrition, and rest. Sympathomimetic stimulation can leave the body depleted — gentle movement is preferable to strenuous activity for at least 48 hours.
Psychological integration follows the same principles as other psychedelics: journaling soon after the experience, discussing the content with a trusted person, and allowing several days before drawing conclusions. If disturbing content emerged, or if anxiety or perceptual disturbances persist beyond a week, seek a mental health professional experienced in psychedelic-related concerns.
Recovery & Support
DOC does not produce physical dependence, and compulsive use is rare due to rapid tolerance. If DOC or other psychedelic use has become a recurring coping mechanism, or is causing distress, harm to relationships, or functional impairment, support is available.
The Fireside Project (62-FIRESIDE / 623-473-7433) provides a psychedelic peer support line. SAMHSA's National Helpline (1-800-662-4357) offers free referrals for substance use concerns. Integration therapists listed through the MAPS directory specialize in processing difficult psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an Emergency
Most DOC experiences involve discomfort but not danger. The following signs indicate a medical emergency requiring immediate help:
- Seizures or uncontrolled muscle rigidity
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown)
- Self-harm behavior or complete detachment from reality
Immediate Steps
- Call emergency services immediately if any of the above signs appear.
- Move the person to a cool, quiet environment. Remove excess clothing if they are overheating.
- Place an unconscious but breathing person in the recovery position (on their side).
- Do not restrain the person unless they are in immediate physical danger.
- Do not induce vomiting.
- Stay with them until help arrives. Monitor breathing and temperature.
What to Tell the Dispatcher
State that the person has taken a psychedelic stimulant (DOC or a DOx compound), the approximate amount and time of ingestion, and the symptoms being observed. In many jurisdictions, Good Samaritan laws protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
DOC occupies a complex regulatory position internationally.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not formally scheduled (as of April 2026) | DEA proposed Schedule I placement in April 2022[20]} and December 2023[21]}. Administrative hearing stayed June 2024 pending US District Court decision. Potentially prosecutable under the Federal Analogue Act given structural similarity to DOM (Schedule I). |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the generic N-alkyl substituted amphetamine provision[17] |
| Germany | Anlage I (BtMG) | Most restrictive category; prohibits possession, trafficking, and manufacture except for authorized research |
| Canada | Schedule I (CDSA) | Scheduled as a hallucinogenic amphetamine analog |
| Australia | Restricted import (Customs Regulations Schedule 4) | Listed as an alkoxyamphetamine; additional state-level prohibition under poisons schedules |
| International (UN) | WHO ECDD recommended Schedule I (1971 Convention) | Recommendation made at 42nd ECDD meeting (2019);[5] formal CND scheduling action required for convention placement |
Analog Act Considerations
In the United States, DOC's structural similarity to DOM (Schedule I) makes it potentially prosecutable under the Federal Analogue Act even without formal scheduling[20]}. DEA rulemaking to formally schedule DOC has faced procedural delays since 2022, with an administrative hearing stayed in June 2024 pending judicial review[21]}.
Legal status varies by jurisdiction and changes frequently. This information reflects the state of law as of April 2026 and is not legal advice.
references
- [1]
- [2] ^abcWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abCoutts RT, Malicky JL (1973) The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). — Canadian Journal of Chemistry doi:10.1139/v73-210
- [4]
- [5]
- [6] ^abcBarnett RY, Baker DD, Kelly NE, McGuire CE, Fassette TC, Gorniak JM (2014) A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report. — Journal of Analytical Toxicology doi:10.1093/jat/bku087